Aurobindo Pharma Ltd - Fell Short of Expectations Amidst Mixed Market Performance
Aurobindo Pharma's Q2FY25 results were below expectations, with US revenue of $421 Mn showing minimal growth QoQ , injectable sales experienced a...
223 Views
Axis Top Picks for the Month of November 2024
The Axis Top Picks Basket delivered a return of 11.6% in the last six months against the 7.5% returns posted by Nifty 50 over the same period.
373 Views
APAC Healthcare Weekly (Nov 3)- Eisai, Takeda, Shionogi, Astellas Pharma, Celltrion, Wuxi AppTec
Large APAC healthcare companies are reporting mixed earnings. Demography will play a key role in ensuring how the overall domestic demand scenario...
751 Views
India: Potential Free Float Changes & Passive Flows in November
Changes to shareholding patterns could lead to changes in float for some stocks in local/global indices. Passive trackers will need to trade over 4...
764 Views
Rubicon Research Pre-IPO - Robust Product Development Pipeline Driving Revenue Growth
Rubicon Research Limited is looking to raise about US$130m in its India IPO. In this note, we talk about the company’s historical performance.
446 Views